Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2016 - 2026)

Ocular Therapeutix has reported Shares Outstanding (Weighted Average) over the past 14 years, most recently at $224.1 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 32.29% year-over-year to $224.1 million; the TTM value through Mar 2026 reached $224.1 million, up 32.29%, while the annual FY2025 figure was $187.2 million, 18.31% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $224.1 million at Ocular Therapeutix, up from $187.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $224.1 million in Q1 2026 and troughed at $76.7 million in Q1 2022.
  • A 5-year average of $127.6 million and a median of $132.0 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 0.36% in 2022 and later skyrocketed 112.47% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $76.9 million in 2022, then increased by 3.84% to $79.8 million in 2023, then surged by 98.26% to $158.3 million in 2024, then rose by 18.31% to $187.2 million in 2025, then increased by 19.68% to $224.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for OCUL at $224.1 million in Q1 2026, $187.2 million in Q4 2025, and $183.9 million in Q3 2025.